retatrutide phase 3 results october 2025 Eli Lilly's Shows Promising Weight Loss | Joshua Silverman posted on the topic Eli Lilly's retatrutide drug, not

Additionally, a multi-country study found substantial demand for GLP-1 medications among people without medical indications, highlighting the evolving landscape of body image and obesity treatment (Jensen et al., 2025)

Your comfort matters more than clean-plate club

Image source: GLP-1s and Food Noise One of the interesting impacts of the GLP1 medications is the reduction of what is called food noise, also known as food-related intrusive thoughts or food preoccupation (Mozafariun 2025)

Discovery and characterization of taspoglutide, a novel analogue of human glucagon-like peptide-1, engineered for sustained therapeutic activity in type 2 diabetes

For women in perimenopause and menopause, dosing decisions should follow a structured evaluation

Kanehisa, M